ClearBridge Large Cap Growth ESG Strategy Q4 2024 Commentary
The ClearBridge Large Cap Growth ESG Strategy underperformed its Russell 1000 Growth Index benchmark in the fourth quarter.
Future Market Insights23h
Global Cholesterol and Lipid Test Market is projected to reach USD 6.2 Billion by 2034 expand at a 7.6% CAGR
The global cholesterol and lipid test market value is anticipated to expand from USD 3.0 billion in 2024 to USD 6.2 billion ...
FDA approves Ozempic to reduce risks from chronic kidney disease in diabetes patients
Ozempic has now also been approved by the US Food and Drug Administration to reduce certain risks associated with chronic ...
HealthDay on MSN7h
FDA Approves Ozempic to Protect Kidneys in Patients With Type 2 Diabetes
A popular diabetes drug just got a major new approval -- and it could be a game-changer for millions of Americans a ...
FDA OK's Ozempic To Protect Kidneys in Type 2 Diabetes Patients
Type 2 diabetes is a leading cause of chronic kidney disease, which affects more than 1 in 7 U.S. adults. The new approval ...
kffhealthnews17h
Ozempic Approved To Treat Chronic Kidney Disease With Type 2 Diabetes
The FDA's move may change how doctors treat chronic kidney disease, which, according to Ozempic maker Novo Nordisk, affects around 37 million Americans and is one of the leading causes of death in the ...
US pauses global funding for key health programme but allows HIV drug access: What is PEPFAR, how does it impact India?
“UNAIDS welcomes this waiver from the US government which ensures that millions of people living with HIV can continue to receive life-saving HIV medication during the assessment of US foreign ...